Geopolitical Tensions Escalate After Putin Vows Retaliation for Ukraine Strike on Drone Unit SoFi Technologies and Ally Financial A Comparative Analysis of Online Banking Platforms Paul Tudor Jones Boosts IREN Stake by 57 in Bet on AI Infrastructure Buildout Another Pet Supplies Store Operator Files Chapter 11 Bankruptcy Amid Sector Challenges Magnificent Seven Deliver Strongest Earnings in Nearly Five Years Raising Bubble Debate Borosil Glass Works Surges Over 200 in One Year on Strong Revenue and EBIDTA Growth TUYA Q1 2026 Earnings Narrow EPS Miss Leaves Stock Flat Amid Steady Operations CYTK Q1 2026 Earnings ClinicalStage Biotech Beats EPS Estimates but Stock Slips TWO Q1 2026 Earnings Strong EPS Beat Masks Investor Caution CTBI Q1 2026 Earnings Earnings Beat Driven by Strong Credit Quality and Operational Discipline Expro Group Holdings XPRO Q1 2026 Earnings GAAP Shortfall Amid Subsea Activity Momentum Patrick Industries PATK Q1 2026 Earnings EPS Beat Amid Modest Revenue Disclosure Strategy Inc Preferred Stock STRC Sees Marginal Decline Amid Tight Trading Range LifeMD LFMD Slips 066 as Stock Hovers Near Established Support Level Maravai LifeSciences MRVI Surges 469 as Biotech Sentiment Improves Tilray Brands TLRY Gains 18 as Cannabis Sector Eyes Key Resistance Pearson PSO Edges Lower as Stock Tests Key Support Zone Trade Court Ruling Invalidates Trumps 10 Blanket Tariffs MetLife Q1 2026 Earnings Strong EPS Beat Highlights Resilient Underwriting Stardust Power SDST Gains 5 as Shares Test Key Resistance Levels SLB Q1 2026 Earnings Marginal EPS Miss Stock Edges Up Amid Mixed Market Signals SMR Q1 2026 Earnings EPS Miss Amid Continued PreRevenue Operations LIND Q1 2026 Earnings Strong Profit Beat Lifts Shares Actinium Pharmaceuticals ATNM Q1 2026 Earnings Narrower Loss Beats Expectations as Development Pipeline Advances VTEX Q1 2026 Earnings EPS Miss Sends Shares Lower Amid Revenue Uncertainty AMT Q1 2026 Earnings EPS Beats Estimates as Operational Stability Supports Results VRDN Q1 2026 Earnings NarrowerthanExpected Loss as Viridian Advances Clinical Pipeline